A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

2013651 citationsJournal Articlehybrid Open Access

Authors

Dae‐Hyun Yoo · Hanyang University Seoul Hospital

Paweł Hrycaj · Poznan University of Medical Sciences

Pedro C. Miranda · Centro de Estudios Científicos

Edgar Ramiterre · Memorial Hospital of South Bend

Mariusz Piotrowski

S. Shevchuk

Volodymyr Kovalenko · Kyiv City Clinical Oncology Center

Nenad Prodanović

Abstract

CT-P13 demonstrated equivalent efficacy to INX at week 30, with a comparable PK profile and immunogenicity. CT-P13 was well tolerated, with a safety profile comparable with that of INX. CLINICALTRIALS.GOV IDENTIFIER: NCT01217086.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of the Rheumatic Diseases

Volume 72, Issue 10, pp. 1613-1620

DOI: 10.1136/annrheumdis-2012-203090

Field-Weighted Citation Impact: 32.60